|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on January 9, 2003; DOI 10.1182/blood-2002-07-2339.
NEOPLASIA
From the Unitat de Bioquímica, Departament de
Ciències Fisiològiques II, Universitat de Barcelona, Campus
de Bellvitge, E-08907 L'Hospitalet de Llobregat, Spain,
and Unitat d'Hematopatologia, Hospital Clínic, Institut
d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
Barcelona, Spain.
Acadesine, 5-aminoimidazole-4-carboxamide (AICA) riboside, induced
apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells in all
samples tested (n = 70). The half-maximal effective concentration
(EC50) for B-CLL cells was 380 ± 60 µM (n = 5). The
caspase inhibitor Z-VAD.fmk completely blocked acadesine-induced apoptosis, which involved the activation of caspase-3, -8, and -9 and
cytochrome c release. Incubation of B-CLL cells with
acadesine induced the phosphorylation of adenosine
monophosphate-activated protein kinase (AMPK), indicating that it is
activated by acadesine. Nitrobenzylthioinosine (NBTI), a nucleoside
transport inhibitor, 5-iodotubercidin, an inhibitor of adenosine
kinase, and adenosine completely inhibited acadesine-induced
apoptosis and AMPK phosphorylation, demonstrating that incorporation of
acadesine into the cell and its subsequent phosphorylation to AICA
ribotide (ZMP) are necessary to induce apoptosis. Inhibitors of
protein kinase A and mitogen-activated protein kinases did not protect
from acadesine-induced apoptosis in B-CLL cells. Moreover, acadesine
had no effect on p53 levels or phosphorylation, suggesting a
p53-independent mechanism in apoptosis triggering. Normal B lymphocytes
were as sensitive as B-CLL cells to acadesine-induced apoptosis.
However, T cells from patients with B-CLL were only slightly affected
by acadesine at doses up to 4 mM. AMPK phosphorylation did not occur in
T cells treated with acadesine. Intracellular levels of ZMP were higher in B-CLL cells than in T cells when both were treated with 0.5 mM
acadesine, suggesting that ZMP accumulation is necessary to activate
AMPK and induce apoptosis. These results suggest a new pathway
involving AMPK in the control of apoptosis in B-CLL cells and raise the
possibility of using acadesine in B-CLL treatment.
(Blood. 2003;101:3674-3680) B-cell chronic lymphocytic leukemia (B-CLL) is
characterized by the accumulation of long-lived B
lymphocytes.1,2 Most of the circulating cells appear to be
nondividing and the clonal excess of B cells is mainly caused by
defects that prevent programmed cell death rather than by alterations
in cell cycle regulation.3 Glucocorticoids and other
chemotherapeutic agents used clinically, including the nucleoside
analogues 2-chloro-2'-deoxyadenosine and fludarabine, induce apoptosis
in B-CLL lymphocytes,4-8 suggesting that apoptosis is the
mechanism of their therapeutic action. Several signaling pathways
regulate apoptosis induced by chemotherapy. Thus, we recently
demonstrated that phosphatidylinositol 3-kinase and protein kinase C
play important roles in the survival of B-CLL cells. Furthermore,
inhibition of these kinases increases glucocorticoid- and
fludarabine-induced apoptosis ex vivo in the presence of survival factors.9
The precursor of nucleotide biosynthesis acadesine or
5-aminoimidazole-4-carboxamide (AICA) riboside has various effects in several types of eukaryotic cells. These effects include inhibition of
growth and depletion of pyrimidine nucleotide pools in
fibroblasts,10,11 accelerated repletion of purine
nucleotide pools in heart,12 reduction of
endurance in skeletal muscle,13 inhibition of fatty acid,
sterol synthesis, and gluconeogenesis in hepatocytes, and increase in
glucose uptake in muscle.14 Acadesine is phosphorylated to
AICA ribotide (ZMP), which mimics 5'-adenosine
monophosphate (AMP) and activates both AMP-activated protein
kinase (AMPK) and AMPK kinase (AMPKK).14,15 The
effects on glucose and lipid metabolism are mediated through activation
of the AMPK cascade.14
Previous studies report that acadesine inhibits
glucocorticoid-induced apoptosis in quiescent
thymocytes,16 apoptosis caused by serum deprivation in
fibroblasts overproducing fructose 2,6-bisphosphate,17 and
ceramide-induced apoptosis in primary astrocytes.18 To
contribute to the understanding of glucocorticoid-induced apoptosis in
B-CLL cells, we attempted to block apoptosis with acadesine and,
surprisingly, we found that acadesine induced apoptosis in B-CLL cells,
whereas T cells from these patients were not affected. Here we study
the mechanism of acadesine-induced apoptosis and propose a new pathway involving AMPK and AMPKK in the control of apoptosis in B-CLL cells.
Patients with B-CLL and cell isolation
T-cell isolation
Reagents Acadesine (5-aminoimidazole-4-carboxamide [AICA] riboside) was obtained from Toronto Research Chemicals (North York, ON, Canada). Adenosine, nitrobenzylthioinosine (NBTI), doxorubicin, oligomycin, DMSO, and propidium iodide (PI) were from Sigma Chemicals (St Louis, MO). 5-Iodotubercidin was from Biomol Research Labs (Plymouth Meeting, PA). Annexin V-fluorescein isothiocyanate (FITC) was from Bender MedSystems (Vienna, Austria). Z-VAD.fmk (benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) was from Bachem (Bubendorf, Switzerland). SB 220025, U0126, and H-89 were from Calbiochem (Darmstadt, Germany). SP 600125 was from Tocris (Bristol, United Kingdom).Cell culture Lymphocytes were cultured immediately after thawing or isolation at a concentration of 2 to 5 × 106 cells/mL in RPMI 1640 culture medium supplemented with 10% heat-inactivated fetal calf serum, 1% glutamine, and 1% penicillin-streptomycin at 37°C in a humidified atmosphere containing 5% carbon dioxide.Analysis of apoptosis by flow cytometry Apoptosis was measured by annexin V binding. Exposure of phosphatidylserine was quantified by surface annexin V staining as previously described.19 To analyze apoptosis in T cells from the samples, 500 000 cells were incubated for 24 hours with the indicated factors. Cells were then washed in PBS, and incubated in 50 µL annexin-binding buffer with allophycocyanin (APC)-conjugated anti-CD3 and phycoerythrin (PE)-conjugated anti-CD19 for 10 minutes in the dark. Cells were then diluted with annexin-binding buffer to a volume of 250 µL and incubated with 0.5 µL annexin V-FITC for 15 minutes in the dark. Then, 250 µL annexin-binding buffer and 5 µL PI were added just before flow cytometric analysis. Data were analyzed using Cell Quest software (Becton Dickinson, Mountain View, CA).Western blot analysis Cells were lysed with Laemmli sample buffer or radioimmunoprecipitation assay (RIPA) extraction buffer and Western blot analysis was performed as described previously20 using the following antibodies: polyclonal antiphospho-AMPK (Thr172), polyclonal antiphospho-p53 (Ser15) polyclonal anticleaved caspase-9 (Cell Signaling Technology, Beverly, MA), monoclonal anti-p53 Ab-5 (Neomarkers, Fremont, CA), polyclonal anticaspase-3 (Transduction Laboratories, Lexington, KY), and monoclonal anticaspase-8 (Cell Diagnostica, Münster, Germany). Antibody binding was detected using a secondary antibody conjugated to horseradish peroxidase and the enhanced chemiluminescence (ECL) detection system (Amersham, Buckinghamshire, United Kingdom).Cytochrome c release measurements Release of cytochrome c from mitochondria to cytosol was measured by Western blot as previously described21 with some modifications. Cells (3 × 107) were harvested, washed once, and gently lysed in 150 µL ice-cold lysis buffer (250 mM sucrose, 1 mM EDTA [ethylenediaminetetraacetic acid], 0.1% digitonin, 25 mM Tris [tris(hydroxymethyl)aminomethane], pH 6.8, 1 mM dithiothreitol, 1 µg/mL leupeptin, 1 µg/mL pepstatin, 1 µg/mL aprotinin, 1 mM benzamidine, and 0.1 mM phenylmethylsulfonyl fluoride). Lysates were centrifuged at 12 000g at 4°C for 3 minutes to obtain the fractions. Mitochondrial and cytosolic fractions were lysed with sample buffer and electrophoresed on a 15% polyacrylamide gel and then analyzed by Western blot using monoclonal antibodies against cytochrome c, clone 7H8.2C12 (Pharmingen, San Diego, CA), or cytochrome oxidase subunit II (Molecular Probes, Eugene, OR).Analysis of intracellular nucleotides by HPLC Cells (2 × 107) were used for nucleotide analysis. After incubation, cells were harvested by centrifugation, washed twice with PBS, and again centrifuged. Supernatant was removed, and the nucleotides were extracted from cell pellet with 300 µL ice-cold 10% perchloric acid. The extract was left on ice for 15 minutes, mixed, and subsequently centrifuged at 12 000g for 5 minutes at 4°C. The supernatant was separated from the protein pellet, neutralized with 5.0 M potassium carbonate, and filtered with Ultrafree-MC Centrifugal Filter Units (NMWL 10 000; Millipore, Bedford, MA) by centrifugation at 12 000g for 30 minutes at 4°C. Neutralized extracts were frozen and stored at 80°C until high-performance liquid chromatography (HPLC) analysis
was performed. Samples were centrifuged at 12 000g for 10 minutes to eliminate salts just before analysis. Nucleotide analyses
were carried out as follows. A 40-µL sample was injected onto a
Spherisorb 5 SAX anion exchange column (2.5 × 4.6 mm; Traces, Teknokroma, Spain) using a gradient of 5 mM
NH4H2PO4, pH 2.5 (buffer A) and 500 mM NH4H2PO4, pH 3.9 (buffer B) at a
flow rate of 1 mL/min. A linear gradient was developed over 40 minutes
at 0% buffer B to 100% buffer B. An LKB Model 2152 high-pressure
liquid chromatograph (Bromma, Sweden) equipped with a Kontron 432 detector (Amersham, Uppsala, Sweden) was used. The various peaks
in the extracts were identified by comparison for retention times with known external standards and the relative absorbance at 260 nm. The
following nucleotides were routinely quantified in the extracts: adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), ZMP, guanosine triphosphate (GTP), guanosine diphosphate (GDP), and guanosine monophosphate (GMP). The
results were expressed as nmol/107 cells.
Acadesine induces apoptosis in B-CLL cells Because acadesine (1-2 mM) blocks glucocorticoid-induced apoptosis of quiescent thymocytes,16 we examined whether glucocorticoid-induced apoptosis in B-CLL cells was also blocked by acadesine. We studied the effect of several doses of acadesine, ranging from 50 µM to 1 mM, on the viability of B-CLL cells. Unexpectedly, acadesine induced apoptosis in a dose-dependent manner (Figure 1A) and the half-maximal effective concentration (EC50) was 380 ± 60 µM (n = 5). All the patients were sensitive to acadesine and the viability after incubation with 0.5 mM acadesine for 24 hours decreased from 68% ± 12 % to 26% ± 12% (n = 70). Figure 1B shows the effect of 0.5 mM acadesine on the viability of B-CLL cells from 20 representative patients. The effect of acadesine on the viability of B-CLL cells was the same when cells were isolated and treated in cell culture or treated in the whole blood sample and then isolated, thus indicating that blood components do not affect acadesine-induced apoptosis (data not shown).
Acadesine induced caspase activation and cytochrome c release from mitochondria We examined the role of caspases and the mitochondrial pathway in acadesine-induced apoptosis. When B-CLL cells were incubated with acadesine in the presence of the caspase inhibitor Z-VAD.fmk (200 µM) for 24 hours, apoptosis was completely blocked (Figure 2A). Furthermore, acadesine induced proteolysis and activation of caspase-3 as measured by the disappearance of procaspase-3 (Figure 2B). To study the mechanism leading to activation of caspase-3, we analyzed the effect of acadesine on the activation of caspase-8 and -9. Acadesine induced processing of caspase-8 and -9 in B-CLL cells, as shown by the appearance of their intermediate cleavage products (43/41 kDa and 37 kDa, respectively).
To analyze the involvement of cytochrome c release in acadesine-induced apoptosis, cytosolic and mitochondrial fractions were obtained and the presence of cytochrome c was analyzed by Western blot. As shown in Figure 2C, acadesine produced a decrease of cytochrome c in the mitochondrial fraction and an increase in the cytosolic fraction of B-CLL cells, demonstrating that acadesine induced cytochrome c release. Uptake and phosphorylation of acadesine are required to induce apoptosis and activate AMPK Next, we analyzed whether the apoptotic effect of acadesine was dependent on acadesine uptake. We found that 10 nM NBTI, a nucleoside transport inhibitor,22 completely inhibited acadesine-induced apoptosis in B-CLL cells (Figure 3A). This result indicates that the acadesine uptake through NBTI-sensitive nucleoside transporters is necessary for its apoptotic effect. Inside the cell, acadesine is phosphorylated probably by adenosine kinase11 and then metabolized through different pathways. When B-CLL cells were incubated with 0.2 µM 5-iodotubercidin, an inhibitor of adenosine kinase,23 the apoptotic effect of 0.5 mM acadesine was blocked (Figure 3A). The intracellular accumulation of acadesine can increase the release of adenosine into the extracellular space,24 and it has been reported that adenosine induces apoptosis of B-CLL cells.25 However, addition of adenosine at equimolar concentrations did not induce apoptosis in B-CLL cells, but, on the contrary, protected them from acadesine-induced apoptosis (Figure 3A). HPLC analysis showed that NBTI, 5-iodotubercidine, and adenosine blocked intracellular ZMP accumulation in B-CLL cells treated with 0.5 mM acadesine for 3 hours (data not shown).
ZMP activates AMPK by direct activation via an allosteric AMP site and by promoting its phosphorylation at Thr172.15,26 Thus, we assessed whether AMPK was activated in acadesine-treated B-CLL cells. AMPK is activated by phosphorylation at Thr172 by the upstream AMPKK raising the activity of AMPK at least 50-fold.27 Therefore, we analyzed the activation of AMPK using a specific antibody against the phosphorylated form of AMPK (Thr172). As seen in Figure 3B, treatment of B-CLL cells with 0.5 mM acadesine for 3 hours induced AMPK phosphorylation. This phosphorylation was maintained at least during 18 hours (data not shown). NBTI, 5-iodotubercidin, and adenosine inhibited acadesine-induced AMPK phosphorylation (Figure 3B). Acadesine-induced apoptosis is independent of PKA, ERK, JNK, and p38 MAPK Because protein kinase A (PKA) and mitogen-activated protein kinases (MAPKs) have been involved in the apoptosis of B-CLL cells,28,29 we studied their implication in acadesine-induced apoptosis using selective inhibitors.We analyzed the effect of the PKA inhibitor H-8930 in
acadesine-induced apoptosis. As shown in Figure
4, H-89 did not affect acadesine-induced
apoptosis. To analyze the effect of ERK and JNK in acadesine-induced
apoptosis, we used the MEK inhibitor U012630 and the JNK
inhibitor SP600125.31 As shown in Figure 4, neither U0126
nor SP600125 protected B-CLL cells from acadesine-induced apoptosis.
Moreover, none of these kinase inhibitors blocked AMPK phosphorylation
induced by acadesine in B-CLL cells (data not shown).
Next, we studied the effect of two p38 MAPK inhibitors, SB203580 and PD169316, in acadesine-induced apoptosis. SB203580 and PD169316 protected B-CLL cells from acadesine-induced apoptosis and AMPK phosphorylation, at doses used to inhibit p38 MAPK. However, intracellular accumulation of ZMP was also abrogated by these p38 MAPK inhibitors (data not shown), as it has been recently reported.32 These results indicate that both inhibitors were interfering with acadesine uptake or phosphorylation to ZMP. Next, we analyzed the effect of SB220025, a p38 MAPK-inhibitor that does not interfere with nucleoside transport33 or ZMP accumulation (data not shown). As shown in Figure 4, SB220025 did not protect B-CLL cells from acadesine-induced apoptosis thus indicating that p38 MAPK is not implicated in its apoptotic effect. Taken together, these results indicate that PKA, ERK, JNK, and p38 MAPK are not involved in acadesine-induced apoptosis in B-CLL cells. Acadesine does not induce p53 phosphorylation or accumulation The p53 tumor suppressor protein plays a major role in the cellular response to a wide range of chemotherapeutic drugs.34 DNA damage induces p53 phosphorylation at several residues including Ser15,35 which in turn promotes both the accumulation and functional activation of p53. Very recently, it has been described that acadesine may regulate cell growth via p53 phosphorylation at Ser15, suggesting that AMPK is involved in regulating p53 function.36 To study the role of p53 in acadesine-induced apoptosis we analyzed the effect of this compound on p53 protein levels and p53 phosphorylation at Ser15. When B-CLL cells were incubated with 0.5 mM acadesine there was no effect on p53 levels or p53 phosphorylation (Figure 5). As a control of p53 activation we used doxorubicin (0.8 µM), which induced p53 protein accumulation and phosphorylation. These data demonstrate that acadesine induces apoptosis of B-CLL cells in a p53-independent manner.
Differential effect of acadesine on B and T cells To analyze whether the induction of apoptosis in B-CLL cells was selective to B population, we analyzed the number of apoptotic T cells (CD3+ cells) in 4 B-CLL blood samples treated with several doses of acadesine. Figure 6A shows the results corresponding to 2 representative patients. T cells from B-CLL patients were resistant to acadesine-induced apoptosis at doses up to 1 mM. Higher concentrations of acadesine (2-4 mM) only slightly affected the viability of T cells. Furthermore, when lymphocytes from B-CLL patients (n = 18) and healthy donors (n = 4) were incubated with 0.5 mM acadesine for 24 hours, viability was markedly reduced in B cells but not in T cells (Figure 6B). These results indicate that B cells are much more sensitive than T cells to acadesine-induced apoptosis.
Then, we analyzed AMPK phosphorylation in T cells obtained from healthy donors. AMPK is not phosphorylated in normal T cells treated with 0.5 mM acadesine for 3 hours (Figure 6C). As a control of AMPK phosphorylation, T cells were treated with 10 µM oligomycin in glucose-free medium for 3 hours, a condition that activates AMPK.37 Next, we measured intracellular ZMP levels by HPLC in B-CLL cells and T cells treated with 0.5 mM acadesine. As shown in Figure 6D, ZMP reached 2.7 ± 0.5 nmol/107 cells for B-CLL cells (n = 6), and 1.1 ± 0.2 nmol/107 cells for T cells (n = 3).
The present study shows that acadesine induces apoptosis in B-CLL cells. These results were unexpected, because acadesine inhibits glucocorticoid-induced apoptosis in quiescent thymocytes,16 apoptosis caused by serum deprivation in fibroblasts overproducing fructose 2,6-bisphosphate,17 and ceramide-induced apoptosis in primary astrocytes.18 In agreement with our results, recently it has been reported that acadesine causes apoptosis in 2 neuroblastoma cell lines38 and a hepatoma cell line.39 These results indicate that acadesine can either induce or inhibit apoptosis depending on the cell type. Mitochondria-mediated apoptosis occurs in response to a wide range of death stimuli, including chemotherapeutic agents.40 In the mitochondrial pathway, cytochrome c and other apoptogenic proteins are released from the mitochondrial intermembrane space to the cytosol. Once released, cytochrome c binds to Apaf-1 and induces activation of caspase-9.41 Our results demonstrate that acadesine induces release of cytochrome c from mitochondria triggering caspase-9 activation and apoptosis in B-CLL cells. The activation of caspase-8 could be explained by a positive loop involving caspase-9, caspase-3, and caspase-6, as described in other cells,42 although the involvement of caspases upstream the mitochondria cannot be discarded. The transporters of acadesine into the cell have not been studied previously. One inhibitor of nucleoside transport, NBTI, blocked acadesine-induced apoptosis, demonstrating that uptake of acadesine through NBTI-sensitive transporters is a necessary step for its apoptotic effect. There are at least 7 different systems responsible for nucleoside transport in mammalian cells: 2 equilibrative and 5 concentrative Na+-dependent transporters. One equilibrative (es) and one concentrative (N5) transport system can be inhibited by nanomolar concentrations of NBTI.22 Interestingly, this concentrative transporter is expressed in NB4 leukemia cells43 and human B-cell lines.44 Nucleoside transport activity was found in B-CLL cells45 and, recently, the expression of the 5 cloned nucleoside transporters in B-CLL cells has been studied.46 Further studies are necessary to characterize the acadesine transporters in B and T cells. This might be therapeutically relevant because a more active nucleoside transport in B cells than in T cells could explain the differential sensitivity to acadesine. The necessary transport of acadesine into the cell rules out the possibility that this compound induces apoptosis through binding to purine receptors, which induce death in various cell types.47 The intracellular accumulation of acadesine leads to increased release of adenosine into the extracellular space.24 Adenosine can induce apoptosis in several cells including B-CLL cells.25 However, we rule out extracellular adenosine accumulation as the mechanism of acadesine-induced apoptosis, because addition of equimolar concentrations of adenosine to B-CLL cells did not induce apoptosis. Indeed, it protected them from acadesine-induced apoptosis. The effect of adenosine could be explained by competition with acadesine transport, but also by competition with an intracellular metabolizing enzyme or target. An initial step in the metabolism of acadesine is its conversion into ZMP by a nucleoside kinase, probably adenosine kinase.11 This step seems to be essential for acadesine-induced apoptosis because inhibition of adenosine kinase by 5-iodotubercidin protects the cells. Whether accumulation of ZMP, or a metabolite derived from ZMP, is the cause of acadesine-induced apoptosis is unknown. ZMP activates AMPK and AMPKK.15,26 Once activated, AMPKK phosphorylates AMPK in Thr172 raising its activity at least 50-fold.27 Our data show that acadesine activates AMPK and AMPKK in B-CLL cells at a concentration that induces apoptosis. Of note, inhibition of ZMP accumulation blocks both activation of AMPK and apoptosis in B-CLL cells. These results suggest a new proapoptotic signaling pathway involving AMPK. PKA and MAP kinases have been involved in the apoptosis of B-CLL cells.28,29 Moreover, JNK has been involved in acadesine-induced apoptosis in a hepatoma cell line.39 However, our results using selective inhibitors indicate that PKA, ERK, JNK, and p38 are not implicated in acadesine-induced apoptosis in B-CLL cells. Recently, Inamura et al reported that acadesine treatment suppressed cell growth in HepG2 cells, associated with p53 phosphorylation at Ser15 and its accumulation, suggesting that AMPK might have a role in the regulation of p53.36 Our data demonstrate that in B-CLL cells the activation of AMPK and AMPKK induced by acadesine does not affect p53 phosphorylation or accumulation, indicating that acadesine-induced apoptosis is p53-independent, an important difference with respect to other nucleoside analogues including fludarabine, which induces p53 stabilization.48 One important point is the selectivity and the concentration of acadesine necessary to induce apoptosis. We have studied the effects of acadesine in different cell lines including EHEB, Jurkat, JVM-2, MCF-7, HEK-293, HeLa, and HUH7 (data not shown). All these cell lines were less sensitive than B-CLL cells. More interestingly, here we show that T cells from B-CLL patients are resistant to acadesine-induced apoptosis, which may be useful in the therapy of B-CLL. The finding that ZMP levels in T cells treated with acadesine are lower than those in B-CLL cells, and are not sufficient to activate AMPK, may explain the resistance of T cells to acadesine-induced apoptosis. Fludarabine and other nucleosides are highly effective in the treatment of B-CLL, either alone or in combination with other agents.2 However, these nucleosides induce apoptosis of T cells48,49 leading to immunosuppression.50,51 Thus, the differential effect of acadesine in B and T lymphocytes is of great interest. Acadesine is well tolerated by healthy individuals when given intravenously, achieving concentrations in plasma (200 µM)52 in the range of those producing apoptosis in B-CLL cells. Moreover, clinical studies in patients undergoing coronary artery bypass graft (CABG) surgery demonstrate that treatment with acadesine before and during surgery can reduce early cardiac death and myocardial infarction.53 In conclusion, present results suggest a new pathway involving AMPK in the control of apoptosis in B-CLL cells and raise the possibility of using acadesine or other AMPK activators in B-CLL treatment.
The authors thank Dr Gabriel Pons, Dr Marçal Pastor-Anglada, Dr Esther Castaño, Dr Maria Piqué, Daniel Iglesias, and Llorenç Coll for helpful discussions and suggestions; Dr Mireia Dalmau for the technical support on flow cytometry analysis; and Maria Reixach and Teresa Barajas from the Serveis Científico-Tècnics at the Universitat de Barcelona for the technical support on HPLC analysis. We also thank R. Rycroft for language assistance.
Submitted August 1, 2002; accepted December 23, 2002.
Prepublished online as Blood First Edition Paper, January 9, 2003; DOI 10.1182/blood-2002-07-2339.
Supported by grant SAF2001-3026 from the Ministerio de Ciencia y Tecnología and Fondo Europeo de Desarrollo Regional (FEDER) (J.G.). C.C. is recipient of a research fellowship from the Fundación Ramón Areces, and A.F.S. and M.B are recipients of a research fellowship from the Ministerio de Ciencia y Tecnología.
C.C. and J.M.L. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Joan Gil, Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, c/ Feixa Llarga s/n, E-08907 L'Hospitalet de Llobregat, Spain; e-mail: joangil{at}bellvitge.bvg.ub.es.
1. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 1998;5:244-253[Medline] [Order article via Infotrieve]. 2. Keating MJ. Chronic lymphocytic leukemia. Semin Oncol. 1999;26:107-114[Medline] [Order article via Infotrieve]. 3. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol. 1998;25:11-18[Medline] [Order article via Infotrieve]. 4. McConkey DJ, Aguilar-Santelises M, Hartzell P, et al. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol. 1991;146:1072-1076[Abstract]. 5. Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA. 2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv Exp Med Biol. 1991;309A:15-18[Medline] [Order article via Infotrieve].
6.
Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB.
Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.
Proc Natl Acad Sci U S A.
1992;89:2970-2974
7.
Robertson LE, Chubb S, Meyn RE, et al.
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Blood.
1993;81:143-150
8.
Bellosillo B, Dalmau M, Colomer D, Gil J.
Involvemente of CDE-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells.
Blood.
1997;89:3378-3384
9.
Barragán M, Bellosillo B, Campàs C, Colomer D, Pons G, Gil J.
Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells.
Blood.
2002;99:2969-2976 10. Thomas CB, Meade JC, Holmes EW. Aminoimidazole carboxamide ribonucleoside toxicity: a model for study of pyrimidine starvation. J Cell Physiol. 1981;107:335-344[CrossRef][Medline] [Order article via Infotrieve].
11.
Sabina RL, Patterson D, Holmes EW.
5-Amino-4-imidazolecarboxamide riboside (Z-riboside) metabolism in eukaryotic cells.
J Biol Chem.
1985;260:6107-6114
12.
Swain JL, Hines JJ, Sabina RL, Holmes EW.
Accelerated repletion of ATP and GTP pools in postischemic canine myocardium using a precursor of purine de novo synthesis.
Cir Res.
1982;51:102-105 13. Swain JL, Hines JJ, Sabina RL, Harbury OL, Holmes EW. Disruption of the purine nucleotide cycle by inhibition of adenylosuccinate lyase produces skeletal muscle dysfunction. J Clin Invest. 1984;74:1422-1427[Medline] [Order article via Infotrieve]. 14. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem. 1998;67:821-855[CrossRef][Medline] [Order article via Infotrieve]. 15. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells. Eur J Biochem. 1998;229:558-565. 16. Stefanelli C, Stanic I, Bonavita F, et al. Inhibition of glucocorticoid-induced apoptosis with 5-aminoimidazole-4-carboxamide ribonucleoside, a cell-permeable activator of AMP-activated protein kinase. Biochem Biophys Res Commun. 1998;243:821-826[CrossRef][Medline] [Order article via Infotrieve]. 17. Durante P, Gueuning M-A, Darville MI, Hue L, Rousseau GG. Apoptosis induced by growth factor withdrawal in fibroblasts overproducing fructose 2,6-bisphosphate. FEBS Lett. 1999;448:239-243[CrossRef][Medline] [Order article via Infotrieve]. 18. Blázquez C, Geelen MJH, Velasco G, Guzmán M. The AMP-activated protein kinase prevents synthesis de novo and apoptosis in astrocytes. FEBS Lett. 2001;489:149-153[CrossRef][Medline] [Order article via Infotrieve].
19.
Bellosillo B, Piqué M, Barragán M, et al.
Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells.
Blood.
1998;92:1406-1414 20. Piqué M, Barragán M, Dalmau M, Bellosillo B, Pons G, Gil J. Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett. 2000;480:193-196[CrossRef][Medline] [Order article via Infotrieve].
21.
Chandra J, Niemer I, Gilbreath J, et al.
Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes.
Blood.
1998;92:4220-4229 22. Pastor-Anglada M, Felipe A, Casado FJ. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends Pharmacol Sci. 1998;19:424-430[CrossRef][Medline] [Order article via Infotrieve]. 23. Henderson JF, Paterson ARP, Caldwell IC, Paul B, Chan MC, Lau KF. Inhibitors of nucleoside and nucleotide metabolism. Cancer Chemother Rep. 1972;3:71-85.
24.
Gruber HE, Hoffer ME, McAllister DR, et al.
Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury.
Circulation.
1989;80:1400-1411
25.
Bajaj S, Insel J, Quagliata F, Hirschhorn R, Silber R.
Adenosine and adenosine analogues are more toxic to chronic lymphocytic leukemia than to normal lymphocytes.
Blood.
1983;62:75-80 26. Abbud W, Habinowski S, Zhang JZ, et al. Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Arch Biochem Biophys. 2000;380:347-352[CrossRef][Medline] [Order article via Infotrieve].
27.
Hawley SA, Davison M, Woods A, et al.
Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase.
J Biol Chem.
1996;271:27879-27887 28. Kim DH, Lerner A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood. 1996;92:2484-2494.
29.
Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J.
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
Blood.
2002;99:1314-1319 30. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105[CrossRef][Medline] [Order article via Infotrieve].
31.
Bennett BL, Sasaki DT, Murray BW, et al.
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
Proc Natl Acad Sci U S A.
2001;98:13681-13686 32. Fryer LG, Parbu-Patel A, Carling D. Protein kinase inhibitors block the stimulation of the AMP-activated protein kinase by 5-amino-4-imidazolecarboxamide riboside. FEBS Lett. 2002;531:189-192[CrossRef][Medline] [Order article via Infotrieve].
33.
Huang M, Wang Y, Collins M, Gu JJ, Mitchell BS, Graves LM.
Inhibition of nucleoside transport by p38 MAPK inhibitors.
J Biol Chem.
2002;277:28364-28367 34. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310[CrossRef][Medline] [Order article via Infotrieve]. 35. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 1998;95:5-8[CrossRef][Medline] [Order article via Infotrieve].
36.
Inamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H.
Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1- 37. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol. 2000;10:1247-1255[CrossRef][Medline] [Order article via Infotrieve]. 38. Pesi R, Micheli V, Jacomelli G, et al. Cytosolic 5'-nucleotidase hyperactivity in erythrocytes of Lesch-Nyhan syndrome patients. Neuroreport. 2000;11:1827-1831[Medline] [Order article via Infotrieve]. 39. Meisse D, Van de Casteele M, Beauloye C, et al. Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett. 2002;526:38-42[CrossRef][Medline] [Order article via Infotrieve].
40.
Green DR, Reed JC.
Mitochondria and apoptosis.
Science.
1998;281:1309-1312
41.
Wang X.
The expanding role of mitochondria in apoptosis.
Genes Dev.
2001;15:2922-2933
42.
Slee EA, Harte MT, Kluck RM, et al.
Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner.
J Cell Biol.
1999;144:281-292
43.
Flanagan S, Meckling-Gill KA.
Characterization of a novel Na+-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells.
J Biol Chem.
1997;272:18026-18032
44.
Soler C, Felipe A, Mata JF, Casado J, Celada A, Pastor-Anglada M.
Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alpha in human B-lymphocytes.
J Biol Chem.
1998;273:26939-26945 45. Petersen AJ, Brown RD, Gibson J, et al. Nucleoside transporters, bcl-2 and apopotosis in CLL cells exposed to nucleoside analogues in vitro. Eur J Haematol. 1996;56:213-220[Medline] [Order article via Infotrieve]. 46. Molina-Arcas M, Bellosillo B, Casado FJ, et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood. In press. 47. Chow SC, Kass GEN, Orrenius S. Purines and their roles in apoptosis. Neuropharmacology. 1997;36:1149-1156[CrossRef][Medline] [Order article via Infotrieve].
48.
Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J.
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Blood.
1999;94:2836-2843
49.
Consoli U, ElTounsi I, Sandoval A, et al.
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
Blood.
1998;91:1742-1748
50.
Keating MJ.
Immunosuppression with purine analogues: the flip side of the gold coin.
Ann Oncol.
1993;4:347-348
51.
Seymour JF, Kurzrock R, Freireich EH, Estey E.
2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.
Blood.
1994;83:2906-2911 52. Dixon R, Gourzis J, McDermott D, Fujitaki J, Dewland P, Gruber H. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol. 1991;31:342-347[Abstract].
53.
Mangano DT.
Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group.
JAMA.
1997;277:325-332
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  R. N. Bose, L. Maurmann, R. J. Mishur, L. Yasui, S. Gupta, W. S. Grayburn, H. Hofstetter, and T. Salley Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells PNAS, November 25, 2008; 105(47): 18314 - 18319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Schulz, J. Dopheide, S. Schuhmacher, S. R. Thomas, K. Chen, A. Daiber, P. Wenzel, T. Munzel, and J. F. Keaney Jr Suppression of the JNK Pathway by Induction of a Metabolic Stress Response Prevents Vascular Injury and Dysfunction Circulation, September 23, 2008; 118(13): 1347 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Riboulet-Chavey, F. Diraison, L. K. Siew, F. S. Wong, and G. A. Rutter Inhibition of AMP-Activated Protein Kinase Protects Pancreatic {beta}-Cells From Cytokine-Mediated Apoptosis and CD8+ T-Cell-Induced Cytotoxicity Diabetes, February 1, 2008; 57(2): 415 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dagon, Y. Avraham, Y. Ilan, R. Mechoulam, and E. M. Berry Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase FASEB J, August 1, 2007; 21(10): 2431 - 2441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Bokko, L. Francione, E. Bandala-Sanchez, A. U. Ahmed, S. J. Annesley, X. Huang, T. Khurana, A. R. Kimmel, and P. R. Fisher Diverse Cytopathologies in Mitochondrial Disease Are Caused by AMP-activated Protein Kinase Signaling Mol. Biol. Cell, May 1, 2007; 18(5): 1874 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Towler and D. G. Hardie AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling Circ. Res., February 16, 2007; 100(3): 328 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Coll-Mulet, D. Iglesias-Serret, A. F. Santidrian, A. M. Cosialls, M. de Frias, E. Castano, C. Campas, M. Barragan, A. F. de Sevilla, A. Domingo, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells Blood, May 15, 2006; 107(10): 4109 - 4114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Andersson, H. Le, S. Juell, and O. Fodstad AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death. Mol. Cancer Ther., April 1, 2006; 5(4): 1050 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dagon, Y. Avraham, I. Magen, A. Gertler, T. Ben-Hur, and E. M. Berry Nutritional Status, Cognition, and Survival: A NEW ROLE FOR LEPTIN AND AMP KINASE J. Biol. Chem., December 23, 2005; 280(51): 42142 - 42148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Santidrian, C. Campas, L. Coll-Mulet, D. Iglesias-Serret, A. M. Cosialls, M. Defrias, A. Domindo, A. F. de Sevilla, G. Pons, and J. Gil Mechanism of Acadesine-Induced Apoptosis in B-Cell Neoplasms. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 4822 - 4822. [Abstract]
|
|
|
|
|
|
M. Igata, H. Motoshima, K. Tsuruzoe, K. Kojima, T. Matsumura, T. Kondo, T. Taguchi, K. Nakamaru, M. Yano, D. Kukidome, et al. Adenosine Monophosphate-Activated Protein Kinase Suppresses Vascular Smooth Muscle Cell Proliferation Through the Inhibition of Cell Cycle Progression Circ. Res., October 14, 2005; 97(8): 837 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nath, S. Giri, R. Prasad, M. L. Salem, A. K. Singh, and I. Singh 5-Aminoimidazole-4-Carboxamide Ribonucleoside: A Novel Immunomodulator with Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis J. Immunol., July 1, 2005; 175(1): 566 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nagata, R. Takeda, M. Sata, H. Satonaka, E. Suzuki, T. Nagano, and Y. Hirata AMP-Activated Protein Kinase Inhibits Angiotensin II-Stimulated Vascular Smooth Muscle Cell Proliferation Circulation, July 27, 2004; 110(4): 444 - 451. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
T cells (
,
) or
CD3
,
) as described in
"Patients, materials, and methods." Two representative patients of
4 analyzed are shown. Viability is expressed as the percentage of the
viability of nontreated cells. (B) Comparison between the induction of
apoptosis in B and T cells (black bars and white bars, respectively)
from B-CLL patients and healthy donors. Cells from 18 patients and 4 healthy donors were incubated with 0.5 mM acadesine for 24 hours.
Viability is expressed as the mean value ± SD. (C) T
cells from healthy donors were cultured with or without 0.5 mM
acadesine for 3 hours and whole cell extracts were analyzed by Western
blot with an antibody against phospho-AMPK (Thr172). As a control for
AMPK activation, cells were incubated with 10 µM oligomycin for 3 hours in glucose-free medium. (D) Cells were cultured with or without
0.5 mM acadesine for 3 hours and intracellular levels of ZMP were
measured by HPLC, as described in "Patients, materials, and
methods." Mean values ± SD from 5 B-CLL samples and 3 T-cell
samples are shown.
-D-ribofuranoside, in a human hepatocellular carcinoma cell line.
Biochem Biophys Res Commun.
2001;287:562-567